This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

4 Biotech Stocks Under $5 Moving Higher

Keryx Biopharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Keryx Biopharmaceuticals (KERX - Get Report) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease. This stock is trading up 4.4% at $2.14 in recent trading.

Today's Range: $2.04-$2.17

52-Week Range: $1.28-$5.19

Volume: 1.2 million

Three-Month Average Volume: 1.15 million

Shares of KERX are moving notably higher today in front of its upcoming presentation at the Stifel Nicolaus 2012 Healthcare Conference on Thursday. The company will also be presenting at Rodman & Renshaw's Annual Global Investment Conference on Sept. 10 and at the UBS Global Life Sciences Conference on Sept. 20.

>>5 Stocks Poised for Big Breakouts

From a technical perspective, KERX is moving higher here right near its 50-day moving average of $1.95 with above average volume. This move is quickly pushing KERX within range of triggering a major breakout trade. That trade will hit once KERX takes out some near-term overhead resistance levels at $2.22 to $2.34, and then its 200-day moving average of $2.44 with high volume.

Traders should now look for long-biased trades in KERX once it sustains a move or close above those levels with volume that's near or above 1,154,840 share. If that breakout triggers soon, then KERX will have a great chance of getting into a previous gap down zone that started above $5.

To see more stocks that are making notable moves higher today, check out the Stocks Under $10 Moving Higher portfolio on Stockpickr.

-- Written by Roberto Pedone in Winderemere, Fla.

RELATED LINKS:



Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Windermere, Fla., is an independent trader who focuses on stocks, options, futures, commodities and currencies. He is also an outside contributor to Beconequity.com and maintains the website Maddmoney.net, which he sold to Blue Wave Advisors in 2008. Roberto studied International Business at The Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany.

5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CDXS $4.74 -6.69%
KERX $11.58 1.14%
PSTI $2.84 1.07%
OREX $7.55 0.13%
AAPL $127.60 2.28%

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs